HKD3.31
0.61% yesterday
Hong Kong, Nov 15, 09:08 am CET
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Sino Biopharmaceutical Target price 2024 - Analyst rating & recommendation

Sino Biopharmaceutical Classifications & Recommendation:

Buy
96%
Hold
4%

Sino Biopharmaceutical Price Target

Target Price HKD4.57
Price HKD3.31
Potential
Number of Estimates 23
23 Analysts have issued a price target Sino Biopharmaceutical 2025 . The average Sino Biopharmaceutical target price is HKD4.57. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 28 analysts: 27 Analysts recommend Sino Biopharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sino Biopharmaceutical stock has an average upside potential 2025 of . Most analysts recommend the Sino Biopharmaceutical stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Billion HKD 28.95 32.25
13.50% 11.39%
EBITDA Margin 25.87% 26.44%
3.18% 2.22%
Net Margin 8.87% 11.97%
1.15% 34.99%

26 Analysts have issued a sales forecast Sino Biopharmaceutical 2024 . The average Sino Biopharmaceutical sales estimate is

HKD32.2b
Unlock
. This is
11.19% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD35.7b 22.99%
Unlock
, the lowest is
HKD29.8b 2.64%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 HKD29.0b 13.50%
2024
HKD32.2b 11.39%
Unlock
2025
HKD35.4b 9.77%
Unlock
2026
HKD39.2b 10.82%
Unlock
2027
HKD30.4b 22.55%
Unlock
2028
HKD31.3b 3.10%
Unlock

19 Analysts have issued an Sino Biopharmaceutical EBITDA forecast 2024. The average Sino Biopharmaceutical EBITDA estimate is

HKD8.5b
Unlock
. This is
12.01% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD11.5b 50.71%
Unlock
, the lowest is
HKD7.1b 6.51%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 HKD7.5b 10.75%
2024
HKD8.5b 13.88%
Unlock
2025
HKD9.0b 6.10%
Unlock
2026
HKD9.9b 9.87%
Unlock

EBITDA Margin

2023 25.87% 3.18%
2024
26.44% 2.22%
Unlock
2025
25.56% 3.33%
Unlock
2026
25.34% 0.86%
Unlock

11 Sino Biopharmaceutical Analysts have issued a net profit forecast 2024. The average Sino Biopharmaceutical net profit estimate is

HKD3.9b
Unlock
. This is
40.37% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD4.8b 74.68%
Unlock
, the lowest is
HKD2.3b 17.21%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 HKD2.6b 12.50%
2024
HKD3.9b 50.40%
Unlock
2025
HKD3.2b 16.60%
Unlock
2026
HKD3.7b 13.81%
Unlock
2027
HKD1.9b 48.39%
Unlock
2028
HKD2.0b 3.85%
Unlock

Net Margin

2023 8.87% 1.15%
2024
11.97% 34.99%
Unlock
2025
9.10% 23.98%
Unlock
2026
9.34% 2.64%
Unlock
2027
6.23% 33.30%
Unlock
2028
6.27% 0.64%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share HKD 0.14 0.21
12.50% 50.00%
P/E 15.72
EV/Sales 2.07

11 Analysts have issued a Sino Biopharmaceutical forecast for earnings per share. The average Sino Biopharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

HKD0.21
Unlock
. This is
40.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
HKD0.26 73.33%
Unlock
, the lowest is
HKD0.12 20.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 HKD0.14 12.50%
2024
HKD0.21 50.00%
Unlock
2025
HKD0.18 14.29%
Unlock
2026
HKD0.20 11.11%
Unlock
2027
HKD0.10 50.00%
Unlock
2028
HKD0.11 10.00%
Unlock

P/E ratio

Current 22.35 25.60%
2024
15.72 29.66%
Unlock
2025
18.85 19.91%
Unlock
2026
16.56 12.15%
Unlock
2027
32.09 93.78%
Unlock
2028
30.90 3.71%
Unlock

Based on analysts' sales estimates for 2024, the Sino Biopharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.31 13.79%
2024
2.07 10.18%
Unlock
2025
1.89 8.90%
Unlock
2026
1.71 9.76%
Unlock
2027
2.20 29.11%
Unlock
2028
2.14 3.01%
Unlock

P/S ratio

Current 2.09 7.54%
2024
1.88 10.07%
Unlock
2025
1.71 8.90%
Unlock
2026
1.55 9.76%
Unlock
2027
2.00 29.10%
Unlock
2028
1.94 3.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today